Emma Hall
Impact in
- Radiation top 0.1%
- Advanced Radiotherapy Techniques
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Papers in
- Radiation 55
- Advanced Radiotherapy Techniques 55
-
- Prostate Cancer Diagnosis and Treatment 63
- Prostate Cancer Treatment and Research 14
- Co-authors
- Robert Anthony Huddart (48 shared papers)Keith Wheatley (3 shared papers)Richard Peto (2 shared papers)Richard G. Gray (2 shared papers)Richard Doll (2 shared papers)Rebecca Lewis (45 shared papers)Christopher M. Nutting (9 shared papers)Kevin Joseph Harrington (8 shared papers)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (38 papers)Clinical Oncology (27 papers)The Lancet Oncology (17 papers)Radiotherapy and Oncology (17 papers)European Urology (12 papers)
- Partner nations
- United KingdomUnited StatesCanada
In The Last Decade
Emma Hall
254 papers receiving 18.6k citations
Emma Hall's Hit Papers
Peers
Comparison fields: 5 of 136
- Radiation 2.6k
- Cancer Research 2.5k
- Pulmonary and Respiratory Medicine 5.6k
- Otorhinolaryngology 884
- Oncology 2.8k
Countries citing papers authored by Emma Hall
This map shows the geographic impact of Emma Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Hall more than expected).
Fields of papers citing papers by Emma Hall
This network shows the impact of papers produced by Emma Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Hall. The network helps show where Emma Hall may publish in the future.
Co-authors
The 25 scholars most cited alongside Emma Hall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 265 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Hit paper breakdown → | 2015 | 1820 |
| 2 | A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer Hit paper breakdown → | 2004 | 1455 |
| 3 | Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial Hit paper breakdown → | 2011 | 1376 |
| 4 | Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Hit paper breakdown → | 2016 | 1016 |
| 5 | Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors Hit paper breakdown → | 1994 | 986 |
| 6 | Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer Hit paper breakdown → | 2012 | 722 |
| 7 | 2007 | 713 | |
| 8 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2019 | 539 |
| 9 | Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Hit paper breakdown → | 2019 | 415 |
| 10 | Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials | 1998 | 413 |
| 11 | Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy Hit paper breakdown → | 2012 | 397 |
| 12 | 2017 | 367 | |
| 13 | Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial Hit paper breakdown → | 2020 | 360 |
| 14 | 2007 | 340 | |
| 15 | 2016 | 286 | |
| 16 | Genomics of lethal prostate cancer at diagnosis and castration resistance Hit paper breakdown → | 2019 | 256 |
| 17 | 2011 | 255 | |
| 18 | Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial Hit paper breakdown → | 2022 | 214 |
| 19 | 1997 | 200 | |
| 20 | 2011 | 196 |
About Emma Hall
Emma Hall is a scholar working on Radiation, Pulmonary and Respiratory Medicine, Surgery, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 265 papers that have together received 19.2k indexed citations. Recurring topics across this work include Prostate Cancer Diagnosis and Treatment (63 papers), Advanced Radiotherapy Techniques (55 papers), Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Treatment and Research (14 papers), Effects of Radiation Exposure (14 papers), PARP inhibition in cancer therapy (12 papers), Head and Neck Cancer Studies (11 papers) and Breast Cancer Treatment Studies (11 papers). The work is most often cited by research in Radiation (2.6k citations), Cancer Research (2.5k citations), Pulmonary and Respiratory Medicine (5.6k citations), Otorhinolaryngology (884 citations) and Oncology (2.8k citations). Emma Hall has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Robert Anthony Huddart, Keith Wheatley, Richard Peto, Richard G. Gray, Richard Doll, Rebecca Lewis, Christopher M. Nutting, Kevin Joseph Harrington, Christopher D. Scrase and Aisha B Miah. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Clinical Oncology, The Lancet Oncology, Radiotherapy and Oncology and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.